Molecular Classification Guides Fertility-Sparing Treatment for Endometrial Cancer and Atypical Hyperplasia Patients
Current Oncology · 2025
DOI: 10.3390/curroncol32060317 ↗Kurz gefasst
Fachartikel in der Zeitschrift Current Oncology, 2025. Verfasst von Yiqin Wang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Peking University People's Hospital, Beijing 100044, China. Hauptthemen laut MEDLINE: Endometrial Neoplasms, Fertility Preservation, Endometrial Hyperplasia. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development Program of China, Natural Science Foundation of Beijing Municipality, Peking University Medicine Fund of Fostering Young Scholars’ Scientific & Technological Innovation.
Abstract (Originalsprache)
Objectives
The objective of this study was to investigate the significance of molecular classification in guiding treatment decisions for patients with endometrial cancer (EC) or atypical hyperplasia (AH) undergoing fertility-sparing treatment (FST), particularly for those with non-NSMP subtypes.
Methods
We conducted a retrospective cohort study involving EC/AH patients undergoing FST and molecular classification using next-generation sequencing at Peking University People’s Hospital between June 2020 and September 2023.
Results
A total of 118 EC/AH patients were included, including 92 cases with NSMP, 11 with MMRd, 11 with POLEmut, and 4 with p53abn. (1) Of the 11 patients with MMRd, 6 achieved a complete response (CR) with 1 case receiving progestin, 3 cases showed insensitivity to the initial progestin before transitioning to a combined regimen of progestin and a PD-1 inhibitor, and 2 cases initially received progestin plus a PD-1 inhibitor. There were no significant differences in the cumulative CR rates between the MMRd and NSMP subgroups but a trend of a lower relapse-free-survival (RFS) rate for the MMRd subgroup (p = 0.074). (2) Of the 11 cases with POLEmut, 10 achieved CR but 4 relapsed. There was also a trend for a lower RFS rate in the POLEmut patients (p = 0.069) compared with the NSMP subgroup. (3) Three of the four patients with p53mut achieved CR after treatment with the GnRHa plus LNG-IUS regimen.
Conclusion
The selection of appropriate regimens may improve FST outcomes in EC/AH patients with molecular classification of non-NSMP subtypes. Immunotherapy is an effective fertility-preserving approach for patients with MMRd.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Obstetrics and Gynecology, Peking University People's Hospital, Beijing 100044, China.
- Department of Gynecology, Fei County People's Hospital, Jining 273400, China.
- Department of Pathology, Peking University People's Hospital, Beijing 100044, China.
ORCID-Profile: Yiqin Wang, Xiaobo Zhang
Förderung
- National Key Research and Development Program of China
- Natural Science Foundation of Beijing Municipality
- Peking University Medicine Fund of Fostering Young Scholars’ Scientific & Technological Innovation
- Peking University People’s Hospital Clinical Research Cultivation Project
Zitieren
APA
Wang, Y., Bo, L., Fan, X., Kang, N., Zhang, X., Tian, L., Zhou, R., & Wang, J. (2025). Molecular Classification Guides Fertility-Sparing Treatment for Endometrial Cancer and Atypical Hyperplasia Patients. Current Oncology. https://doi.org/10.3390/curroncol32060317
Vancouver
Wang Y, Bo L, Fan X, Kang N, Zhang X, Tian L, et al. Molecular Classification Guides Fertility-Sparing Treatment for Endometrial Cancer and Atypical Hyperplasia Patients. Current Oncology. 2025. doi:10.3390/curroncol32060317
BibTeX
@article{Wang2025,
author = {Wang, Yiqin and Bo, Linlin and Fan, Xiaowei and Kang, Nan and Zhang, Xiaobo and Tian, Li and Zhou, Rong and Wang, Jianliu},
title = {Molecular Classification Guides Fertility-Sparing Treatment for Endometrial Cancer and Atypical Hyperplasia Patients},
journal = {Current Oncology},
year = {2025},
doi = {10.3390/curroncol32060317}
}
EUVIMED